132 related articles for article (PubMed ID: 30678836)
1. Hyperosmotic intraventricular drug delivery of DV1 in the management of intracranial metastatic breast cancer in a mouse model.
Krishnamurthy S; Li J; Bodman A; Zhang C; Yang Y; An J
J Clin Neurosci; 2019 Apr; 62():207-211. PubMed ID: 30678836
[TBL] [Abstract][Full Text] [Related]
2. Bifunctional fused polypeptide inhibits the growth and metastasis of breast cancer.
Liang AL; Qian HL; Zhang TT; Zhou N; Wang HJ; Men XT; Qi W; Zhang PP; Fu M; Liang X; Lin C; Liu YJ
Drug Des Devel Ther; 2015; 9():5671-86. PubMed ID: 26527862
[TBL] [Abstract][Full Text] [Related]
3. Intracerebral infusion of the bispecific targeted toxin DTATEGF in a mouse xenograft model of a human metastatic non-small cell lung cancer.
Huang J; Li YM; Massague J; Sicheneder A; Vallera DA; Hall WA
J Neurooncol; 2012 Sep; 109(2):229-38. PubMed ID: 22696210
[TBL] [Abstract][Full Text] [Related]
4. Heading in a new direction: drug permeability in breast cancer brain metastasis.
Sledge GW
Clin Cancer Res; 2010 Dec; 16(23):5605-7. PubMed ID: 21045085
[TBL] [Abstract][Full Text] [Related]
5. Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer.
Lockman PR; Mittapalli RK; Taskar KS; Rudraraju V; Gril B; Bohn KA; Adkins CE; Roberts A; Thorsheim HR; Gaasch JA; Huang S; Palmieri D; Steeg PS; Smith QR
Clin Cancer Res; 2010 Dec; 16(23):5664-78. PubMed ID: 20829328
[TBL] [Abstract][Full Text] [Related]
6. Identification of LY2510924, a novel cyclic peptide CXCR4 antagonist that exhibits antitumor activities in solid tumor and breast cancer metastatic models.
Peng SB; Zhang X; Paul D; Kays LM; Gough W; Stewart J; Uhlik MT; Chen Q; Hui YH; Zamek-Gliszczynski MJ; Wijsman JA; Credille KM; Yan LZ
Mol Cancer Ther; 2015 Feb; 14(2):480-90. PubMed ID: 25504752
[TBL] [Abstract][Full Text] [Related]
7. A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer.
Huang EH; Singh B; Cristofanilli M; Gelovani J; Wei C; Vincent L; Cook KR; Lucci A
J Surg Res; 2009 Aug; 155(2):231-6. PubMed ID: 19482312
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic efficacy and molecular mechanisms of snake (Walterinnesia aegyptia) venom-loaded silica nanoparticles in the treatment of breast cancer- and prostate cancer-bearing experimental mouse models.
Badr G; Al-Sadoon MK; Rabah DM
Free Radic Biol Med; 2013 Dec; 65():175-189. PubMed ID: 23811005
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of CXCR4 by CTCE-9908 inhibits breast cancer metastasis to lung and bone.
Richert MM; Vaidya KS; Mills CN; Wong D; Korz W; Hurst DR; Welch DR
Oncol Rep; 2009 Mar; 21(3):761-7. PubMed ID: 19212637
[TBL] [Abstract][Full Text] [Related]
10. In vivo magnetic resonance imaging investigating the development of experimental brain metastases due to triple negative breast cancer.
Hamilton AM; Foster PJ
Clin Exp Metastasis; 2017 Feb; 34(2):133-140. PubMed ID: 28108861
[TBL] [Abstract][Full Text] [Related]
11. Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2
Priceman SJ; Tilakawardane D; Jeang B; Aguilar B; Murad JP; Park AK; Chang WC; Ostberg JR; Neman J; Jandial R; Portnow J; Forman SJ; Brown CE
Clin Cancer Res; 2018 Jan; 24(1):95-105. PubMed ID: 29061641
[No Abstract] [Full Text] [Related]
12. Peptide density targets and impedes triple negative breast cancer metastasis.
Liu D; Guo P; McCarthy C; Wang B; Tao Y; Auguste D
Nat Commun; 2018 Jul; 9(1):2612. PubMed ID: 29973594
[TBL] [Abstract][Full Text] [Related]
13. Amide-sulfamide modulators as effective anti-tumor metastatic agents targeting CXCR4/CXCL12 axis.
Wu R; Yu W; Yao C; Liang Z; Yoon Y; Xie Y; Shim H; Bai R
Eur J Med Chem; 2020 Jan; 185():111823. PubMed ID: 31698158
[TBL] [Abstract][Full Text] [Related]
14. Vascular endothelial growth factor expression promotes the growth of breast cancer brain metastases in nude mice.
Kim LS; Huang S; Lu W; Lev DC; Price JE
Clin Exp Metastasis; 2004; 21(2):107-18. PubMed ID: 15168728
[TBL] [Abstract][Full Text] [Related]
15. Convection-enhanced delivery of sulfasalazine prolongs survival in a glioma stem cell brain tumor model.
Haryu S; Saito R; Jia W; Shoji T; Mano Y; Sato A; Kanamori M; Sonoda Y; Sampetrean O; Saya H; Tominaga T
J Neurooncol; 2018 Jan; 136(1):23-31. PubMed ID: 28929335
[TBL] [Abstract][Full Text] [Related]
16. Adenosine A2A receptor activation reduces brain metastasis via SDF-1/CXCR4 axis and protecting blood-brain barrier.
Chen L; Li L; Zhou C; Chen X; Cao Y
Mol Carcinog; 2020 Apr; 59(4):390-398. PubMed ID: 32037613
[TBL] [Abstract][Full Text] [Related]
17. Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib.
Zheng N; Liu W; Li B; Nie H; Liu J; Cheng Y; Wang J; Dong H; Jia L
J Exp Clin Cancer Res; 2019 May; 38(1):232. PubMed ID: 31151472
[TBL] [Abstract][Full Text] [Related]
18. Distribution analysis of epertinib in brain metastasis of HER2-positive breast cancer by imaging mass spectrometry and prospect for antitumor activity.
Tanaka Y; Hirata M; Shinonome S; Torii M; Nezasa KI; Tanaka H
Sci Rep; 2018 Jan; 8(1):343. PubMed ID: 29321587
[TBL] [Abstract][Full Text] [Related]
19. CXCL12/CXCR4 Axis-Targeted Dual-Functional Nano-Drug Delivery System Against Ovarian Cancer.
Xue J; Li R; Gao D; Chen F; Xie H
Int J Nanomedicine; 2020; 15():5701-5718. PubMed ID: 32848392
[TBL] [Abstract][Full Text] [Related]
20. Pazopanib reveals a role for tumor cell B-Raf in the prevention of HER2+ breast cancer brain metastasis.
Gril B; Palmieri D; Qian Y; Smart D; Ileva L; Liewehr DJ; Steinberg SM; Steeg PS
Clin Cancer Res; 2011 Jan; 17(1):142-53. PubMed ID: 21081656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]